• Addex reported spin-out Neurosterix remains on track to complete Phase 1 study of NTX-253 for schizophrenia in Q2 2026.
• Results have not been presented yet; readout is expected once Phase 1 completes.
• Trial is designed to build early clinical package on safety, tolerability, pharmacokinetics in healthy adults plus adults with stable schizophrenia.
• Addex retains 20% equity stake in Neurosterix, which raised $65 million in Series A financing in April 2024.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Addex Therapeutics Ltd. published the original content used to generate this news brief on April 23, 2026, and is solely responsible for the information contained therein.